How Intelligencia AI revolutionizes drug development with AI, with Dimitris Skaltsas
What does it take to innovate at the crossroads of technology and life sciences?
This week we are joined by Dimitris Skaltsas, Co-Founder and CEO of Intelligencia AI, an innovative company applying AI and machine learning to de-risk drug development. Intelligencia AI aims to bridge the gap between innovation and risk reduction with an interdisciplinary team of software engineers, AI practitioners, scientists, and drug developers, with the ultimate goal of bringing novel therapies to patients faster.
Dimitris shares insights into balancing innovation with regulation, releasing AI tools at the right moment, and fostering trust-based relationships to bridge the gap between risk and discovery.
🚀Listen to Dimitris discuss how to think fast and slow in start-up culture
https://www.youtube.com/watch?v=HDLq4kdMy9o
Learn more about EUROPE BUILDS: https://byborrn.substack.com/p/does-europe-build-real-innovation
